Inventor · disambiguated record
Khalid Mekouar
Also filed as: MEKOUAR KHALID
8 granted patents·3 pending applications·35 citations·filing 1998–2018
81Inventor score
Files withAHLFORS JAN-ERIC3MICROLOGIX BIOTECH INC3GENESIS TECH LIMITED2AVENTIS PHARMA SA1CENTRE NAT RECHERCHE1
Top patents by PatentIndex Score
11 records- 0180US8791235B2Selective caspase inhibitors and uses thereofAHLFORS JAN-ERIC·Filed 2009·Granted Jul 29, 2014·4 cites·21 claims
- 0277US9045524B2Selective caspase inhibitors and uses thereofAHLFORS JAN-ERIC·Filed 2010·Granted Jun 2, 2015·2 cites·4 claims
- 0375US6670377B1Quinoline derivatives, having in particular antiviral properties, preparation and biological applications thereofCENTRE NAT RECHERCHE·Filed 1998·Granted Dec 30, 2003·25 cites·12 claims
- 0472US10167313B2Selective caspase inhibitors and uses thereofGENESIS TECH LIMITED·Filed 2017·Granted Jan 1, 2019·1 cites·22 claims
- 0571US9944674B2Selective cysteine protease inhibitors and uses thereofAHLFORS JAN ERIC·Filed 2012·Granted Apr 17, 2018·1 cites·26 claims
- 0669US9562069B2Selective caspase inhibitors and uses thereofGENESIS TECH LTD·Filed 2014·Granted Feb 7, 2017·2 cites·25 claims
- 0754US10975119B2Selective cysteine protease inhibitors and uses thereofGENESIS TECH LIMITED·Filed 2018·Granted Apr 13, 2021·0 cites·20 claims
- 0851US2006003951A1Anti-viral 7-deaza L-nucleosidesMICROLOGIX BIOTECH INC·Filed 2005·Application pending·0 cites
- 0948US2003153744A1Anti-viral 7-deaza L-nucleosidesMICROLOGIX BIOTECH INC·Filed 2002·Application pending·0 cites
- 1042US2005026853A1Anti-viral 7-deaza D-nucleosides and uses thereofMICROLOGIX BIOTECH INC·Filed 2003·Application pending·0 cites
- 1130US6500953B1Preparation of camptothecin and nothapodytine derivativesAVENTIS PHARMA SA·Filed 2000·Granted Dec 31, 2002·0 cites·3 claims
Join the waitlist — get patent alerts
Get an alert when Khalid Mekouar files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →